Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

AbbVie Reveals Promising ADC Data for Advanced Cancer Treatments at ASCO 2024

ONCOLife |

3 June 2024

AbbVie presented promising new data at ASCO 2024 for its innovative antibody-drug conjugates (ADCs) targeting advanced cancers. Highlights include efficacy of ABBV-400 in metastatic colorectal cancer, ABBV-706 in small cell lung cancer and neuroendocrine tumors, and Teliso-V in non-small cell lung cancer. These ADCs target specific biomarkers, offering hope for difficult-to-treat tumors.

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, AbbVie revealed compelling new data from its innovative antibody-drug conjugate (ADC) platform, showcasing potential breakthroughs in the treatment of several difficult-to-treat cancers. The company presented findings from studies on three novel ADCs targeting specific protein biomarkers, promising a new era of targeted cancer therapies.

Promising Data for ABBV-400 in Metastatic Colorectal Cancer

One of the highlights was the Phase 1 study of ABBV-400, a next-generation c-Met directed ADC, aimed at patients with metastatic colorectal cancer (CRC). The study enrolled 122 heavily pre-treated patients, demonstrating notable antitumor activity. The results indicated an objective response rate (ORR) of 18% at a 2.4 mg/kg dose and 24% at a 3.0 mg/kg dose, administered once every three weeks.

Patients with higher c-Met expression exhibited even more promising responses, with an ORR exceeding 35% at doses ≥2.4 mg/kg. However, treatment-related adverse events were significant, with anemia (35%), neutropenia (7%), and febrile neutropenia (6%) being the most common severe side effects.

"c-Met overexpression, found in the majority of patients with metastatic CRC, has been reported to be associated with poor prognosis. However, there are no approved therapies specific for c-Met–overexpressing CRCs, making it an attractive cancer biomarker to target. Results from this Phase 1 study show preliminary evidence of efficacy for ABBV-400 in patients with heavily pre-treated colorectal cancer and are supportive of further exploration of this novel ADC in CRC and other solid tumors," said Dr. Manish Sharma, Principal Investigator of the ABBV-400 trial.

Telisotuzumab Vedotin for Advanced Non-Small Cell Lung Cancer

In the Phase 2 LUMINOSITY trial, AbbVie evaluated telisotuzumab vedotin (Teliso-V), another c-Met directed ADC, in patients with advanced non-small cell lung cancer (NSCLC). This ADC utilizes monomethyl auristatin E (MMAE), a microtubule polymerization inhibitor, as its payload. Positive results had been previously announced, underlining the therapeutic potential of this targeted approach in c-Met-overexpressing NSCLC.

ABBV-706 for SCLC and Neuroendocrine Tumors

Another exciting development is the first-in-human study of ABBV-706, a SEZ6 directed ADC, targeting small cell lung cancer (SCLC) and high-grade neuroendocrine neoplasms (NENs). Early data from this study showed a confirmed ORR of 43.8% among 48 efficacy-evaluable patients, with an impressive 60.9% ORR in the SCLC group. The primary adverse events included neutropenia (42%), anemia (42%), and leukopenia (28%).

"Our ADC platform allows us to utilize selected biomarkers such as c-Met and SEZ6 to induce targeted cancer cell death by delivering potent anti-cancer agents. The data we are presenting at ASCO demonstrate the clinical potential of this approach across a wide range of difficult-to-treat tumors," said Dr. Daejin Abidoye, M.D., V.P. Head of Solid Tumors, Oncology Development, AbbVie.

Broader Implications and Future Directions

AbbVie's ADC platform leverages cutting-edge technology to target specific protein biomarkers such as c-Met and SEZ6, which are overexpressed in various tumor types. By delivering potent anti-cancer agents directly to the cancer cells, these ADCs aim to maximize therapeutic efficacy while minimizing systemic toxicity.

In addition to ABBV-400 and ABBV-706, AbbVie also presented findings on mirvetuximab soravtansine (ELAHERE®), an ADC targeting folate receptor-alpha in platinum-resistant ovarian cancer. This comprehensive suite of presentations reflects AbbVie's robust and diverse oncology pipeline, poised to address various unmet needs in cancer therapy.

Related Articles



Comments

No Comments Yet!

Make a Comment!